Novo Nordisk(US:NVO) Zhi Tong Cai Jing·2025-06-27 03:40Core Insights - Novo Nordisk (NVO.US) has entered into a partnership with WeightWatchers (WGHTQ.US) to sell its weight loss drug Wegovy, following the termination of a similar agreement with Hims & Hers Health (HIMS.US) [1] - The new agreement allows WeightWatchers, which filed for Chapter 11 bankruptcy protection in May, to collaborate with CenterWell Pharmacy, a subsidiary of Humana (HUM.US), to sell Wegovy through Novo Nordisk's direct-to-consumer platform, NovoCare Pharmacy [1] - Novo Nordisk's U.S. operations head, Dave Moore, emphasized the alignment of WeightWatchers' long-standing commitment to scientific weight management with Novo Nordisk's goal of improving long-term health outcomes [1] Summary by Sections Partnership Developments - Novo Nordisk has terminated its short-term partnership with Hims & Hers, which previously allowed members to access Wegovy through NovoCare Pharmacy [1] - The new collaboration with WeightWatchers is aimed at enhancing access to Wegovy for patients without insurance coverage [1] Regulatory and Compliance Issues - Novo Nordisk stated that while the shortage of Wegovy has eased, the low-cost compounded version launched by Hims & Hers last year did not comply with federal regulations, leading to strong objections from Hims & Hers CEO Andrew Dudum [2]